Daou Badih, Starke Robert M, Chalouhi Nohra, Barros Guilherme, Tjoumakaris Stavropoula, Rosenwasser Robert H, Jabbour Pascal
Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania.
Neurosurgery. 2016 Jan;78(1):27-33. doi: 10.1227/NEU.0000000000000978.
The main concern with the use of the pipeline embolization device (PED) in treating cerebral aneurysms is the risk of hemorrhagic and thromboembolic complications.
To investigate if P2Y12 reaction unit (PRU) values are associated with hemorrhagic and thromboembolic complications after treatment with the PED and to find an optimal range of preprocedural PRU values.
Two hundred thirty-one patients with 248 cerebral aneurysms treated with the PED were retrospectively identified. Patients were started on dual-antiplatelet treatment at least 10 days before the intervention. PRU values were checked. Univariate and multivariate logistic regression were performed. Youden Indices were calculated to determine cutoffs for optimal PRU values.
Mean patient age was 57 years. Mean last preprocedural PRU was 132 (range: 1-382). The combined rate of major hemorrhagic complications (4%) and major thromboembolic complications (5.6%) was 9.6%. Analysis using Youden indices suggested an optimal PRU range of 70 to 150 with higher odds of complications outside this range (P = .01, odds ratio [OR] = 3 [1.2-7.5]). PRU <60 was a significant predictor of hemorrhagic complications (P = .04, OR = 2.45 [1.01-5.9]) and PRU >240 was a significant predictor of any thromboembolic complication (P = .04, OR = 3.6 [1.04-12]) and cerebral thromboembolic complications (P = .02, OR = 4 [1.2-14]).
Target preoperative PRU values should be between 60 and 240 and ideally between 70 and 150. Values below this range and above it carry higher odds of hemorrhagic and thromboembolic complications, respectively.
使用管道栓塞装置(PED)治疗脑动脉瘤时,主要关注的是出血和血栓栓塞并发症的风险。
研究P2Y12反应单位(PRU)值与PED治疗后出血和血栓栓塞并发症是否相关,并找到术前PRU值的最佳范围。
回顾性纳入231例接受PED治疗248个脑动脉瘤的患者。患者在干预前至少10天开始接受双联抗血小板治疗。检查PRU值。进行单因素和多因素逻辑回归分析。计算约登指数以确定最佳PRU值的临界值。
患者平均年龄为57岁。术前最后一次PRU的平均值为132(范围:1 - 382)。主要出血并发症(4%)和主要血栓栓塞并发症(5.6%)的综合发生率为9.6%。使用约登指数分析表明,最佳PRU范围为70至150,超出此范围并发症发生几率更高(P = 0.01,比值比[OR] = 3[1.2 - 7.5])。PRU <60是出血并发症的显著预测因素(P = 0.04,OR = 2.45[1.01 - 5.9]),PRU >240是任何血栓栓塞并发症(P = 0.04,OR = 3.6[1.04 - 12])和脑血栓栓塞并发症(P = 0.02,OR = 4[1.2 - 14])的显著预测因素。
术前目标PRU值应在60至240之间,理想范围为70至150。低于此范围和高于此范围的值分别具有更高的出血和血栓栓塞并发症发生几率。